IncyteRegister for a premium account to gain access to Sterling AI.
Get StartedThings you can ask Sterling:
Incyte (INCY) reported revenue of $1.67B in Q2 2026, with J A K A F I its largest revenue segment at 59%.
IncyteIncyte commercializes Jakafi/Jakafi XR (ruxolitinib) for myelofibrosis, polycythemia vera, and GVHD, and Opzelura cream for atopic dermatitis and vitiligo. Newer heme/oncology brands include Niktimvo, Minjuvi/Monjuvi, and Zynyz.
Incyte (INCY) is a Biotechnology company. Incyte commercializes Jakafi/Jakafi XR (ruxolitinib) for myelofibrosis, polycythemia vera, and GVHD, and Opzelura cream for atopic dermatitis and vitiligo. Newer heme/oncology brands include Niktimvo, Minjuvi/Monjuvi, and Zynyz. It was founded in 1991, is headquartered in Wilmington, Delaware and employs about 2,844 people.
As of 2026-Q2, Incyte's revenue breaks down across J A K A F I (59%), OPZELURA (28%), M I N J U V I (3%), ZYNYZ (3%). See the revenue-by-segment chart for the full mix.
Track Incyte's quarterly and annual revenue, gross and net margins, and EPS in the interactive charts on this page. Data last updated October 10, 2026.
Sterling groups Incyte in the Healthcare industry, alongside Biogen (BIIB), Gilead Sciences (GILD) and Vertex Pharmaceuticals (VRTX).
If you are researching Incyte, also look at Biogen (BIIB), Gilead Sciences (GILD) and Vertex Pharmaceuticals (VRTX). You can compare all of them side by side or browse the full Healthcare industry on Sterling.
Q3 2016-Q2 2026
Q3 2016-Q2 2026